Date: 2013-02-27
Type of information: Fundraising
Company: EpiTherapeutics (Denmark)
Investors: Novo Seeds (Denmark) SEED Capital Denmark (Denmark) Lundbeckfond Emerge (Denmark) Merck Serono Ventures (Germany - Switzerland)
Amount: € 5 million
Funding type: series A financing round
Planned used: The new financing will support the further advancement of the company’s anti-cancer drug candidates toward clinical development. Epitherapeutics is building a pipeline of novel small-molecule inhibitors against selected epigenetic oncology targets. Epigenetic enzymes are believed to play a key role in numerous human diseases, including oncology.
Others: EpiTherapeutics, a biopharmaceutical company making innovative pharmaceutical agents based on a leading scientific position in the field of epigenetics, has raised € 5 million in a first closing of a Series A round, bringing the total financing raised to DKK 108,7 million (€ 14,6 million) since the inception of Epitherapeutics in October 2008. All major current investors participated in the round, including Novo Seeds, SEED Capital Denmark, Lundbeckfond Emerge and Merck Serono Ventures.
The new financing will support the further advancement of the company’s anti-cancer drug candidates toward clinical development. Epitherapeutics is building a pipeline of novel small-molecule inhibitors against selected epigenetic oncology targets. Epigenetic enzymes are believed to play a key role in numerous human diseases, including oncology.
Therapeutic area: Cancer - Oncology
